2017 年 1 月(No69）の記事要旨と参考文献
参考文献はアクセスが容易になるように、できる限りネットへのリンクをつけたものにしています（特に PubMed アブストラクトへリンクできるよう）1Editorial

p3

Free

http://www.npojip.org/chk_tip/69-Editorial.pdf

総説

p4-7

まとめ
今までは、予防接種が感染防御に大きく役立った感染症があった。しかし、生活環境や栄養の改善で重症化する人が著しく減少する感染症がある。患者数も減るので、予防接種が同じ効果を示しても予防できる人数が減ってしまう。しかし、接種による害は同じ率で発生するので、結局、利害のバランスが逆転し得る。効力を上げようとアジュバント追加が増えてきたが、副作用を増すことになっているのが実情であろう。 予防接種導入の際には、利益/不利益や費用対効果などを検討し、それぞれの状況下で有益性が不利益性をはるかに凌ぐことが求められる。そして、感染症対策には予防接種は防御策の一環と位置づけた総合的施策が必要である。いずれにしても、予防接種への理解を深めて、適切な情報のもとに接種を判断するという医療の基本に立ち返ることが大切である。
参考文献
1) Rotavirus vaccine. Wikipedia. https://en.wikipedia.org/wiki/Rotavirus_vaccine
2) CDC. Intussusception among recipients of rotavirus vaccine: United States, 1998–1999. MMWR
1999;48:577–81.
23) http://www.fda.gov/downloads/biologicsbloodvaccines/vaccines/approvedproducts/ucm142304.pdf
4)Murphy TV, Gargiullo PM, et al. Intussusception among infants given an oral rotavirus vaccine.
N Engl J. Med 2001; 344:564-572 https://www.ncbi.nlm.nih.gov/pubmed/112073525)Kramarz P, France EK, DeStefano F, et al. Population-based study of rotavirus vaccination andintussusception. Pediatr Infect Dis J 2001;20:410-6. https://www.ncbi.nlm.nih.gov/pubmed/11332666
6) Soares-Weiser K et al Vaccines for preventing rotavirus diarrhoea: vaccines in use. Cochrane
Database of Systematic Reviews 2012, Issue 11. Art. No.: CD008521
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008521.pub3/full7)Gulf War and Health: Depleted Uranium, Sarin, Pyridostigmine Bromide,and Vaccines. The Instituteof Medicine, 2000.
https://www.nap.edu/catalog/9953/gulf-war-and-health-volume-1-depleted-uranium-pyridostigmine-bromide8) HPV ワクチン(いわゆる子宮頸がんワクチン)を打った後の難病.薬のチェックTIP 2015; 15(62):140-143. http://www.npojip.org/chk_tip.html#No629) Jefferson T, Di Pietrantonj C, Al-Ansary LA, Ferroni E, Thorning S, Thomas RE.
Vaccines for preventing influenza in the elderly.
Cochrane Database Syst Rev. 2010 Feb 17;(2):CD004876. doi: 10.1002/14651858.CD004876.pub3.
http://onlinelibrary.wiley.com/wol1/doi/10.1002/14651858.CD004876.pub3/full10) Bonten MJ et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia inadults. N Engl J Med 2015;372(12):1114-25.
https://www.ncbi.nlm.nih.gov/pubmed/25785969
11) HPV ワクチン被害と「病者除外バイアス」.薬のチェックTIP 2016;16:62-63.
http://www.npojip.org/chk_tip/No65-file05.pdf
http://www.npojip.org/chk_tip.html#No65
12) Chandler RE et al. Current Safety Concerns with Human Papillomavirus Vaccine: A
Cluster Analysis of Reports in VigiBase®. Drug Saf 2016 Sep 16 [Epub ahead of print]
doi:10.1007/s40264-016-0456-3 https://www.ncbi.nlm.nih.gov/pubmed/27638661
13) Tseng HF et al. Herpes Zoster Vaccine and the Incidence of Recurrent Herpes Zoster in an
Immunocompetent Elderly Population J Infect Dis 2012;206:190-6.
http://dx.doi.org/10.1093/infdis/jis334 https://www.ncbi.nlm.nih.gov/pubmed/22669900
14) RTS,S Clinical Trials Partnership. Efficacy and safety of RTS,S/AS01 malaria vaccine with orwithout a booster dose in infants and children in Africa: final results of a phase 3,
individually randomised, controlled trial. Lancet 2015 386(9988):31-45. doi:
10.1016/S0140-6736(15)60721-8. https://www.ncbi.nlm.nih.gov/pubmed/25913272
15) Regules JA et al. A Recombinant Vesicular Stomatitis Virus Ebola Vaccine - Preliminary
Report. N Engl J Med, April 1, 2015 [Epub ahead of print]
https://www.ncbi.nlm.nih.gov/pubmed/25830322

New Products

p.8-9

薬のチェック TIP 編集委員会

参考文献
1. 日本脂質栄養学会、長寿のためのコレステロールガイドライン 20103

2. 日本脂質栄養学会、続「長寿のためのコレステロールガイドライン」2014
3. Hamazaki T, Okuyama H, Ogushi Y, Hama R. Towards a Paradigm Shift in CholesterolTreatment. A Re-examination of the Cholesterol Issue in Japan. Ann Nutr Metab. 2015;66
Suppl 4:1-116. Free https://www.karger.com/Article/Abstract/381654
4. Ravnskov U, Diamond DM, Hama R, Hamazaki T, Ogushi Y, Okuyama H et al. Lack of anassociation or an inverse association between low-density-lipoprotein cholesterol andmortality in the elderly: a systematic review. BMJ Open. 2016 Jun 12;6(6):e010401 Free
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4908872/pdf/bmjopen-2015-010401.pdf
5.エボロクマブ a)申請資料概要、b)審査報告書
6.アリロクマブ a)申請資料概要、b)審査報告書
7. Raal FJ, Honarpour N, Blom DJ et al(TESLA Investigators). Inhibition of PCSK9with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): arandomised, double-blind, placebo-controlled trial. Lancet. 2015;385(9965):341-50.
https://www.ncbi.nlm.nih.gov/pubmed/25282520
8. Raal FJ, Stein EA, Dufour R, et al (RUTHERFORD-2 Investigators)
PCSK9inhibition
with evolocumab (AMG145)
inheterozygous
familial
hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled
trial. Lancet. 2015; 385(9965):331-40. https://www.ncbi.nlm.nih.gov/pubmed/25282519
9. Blom DJ, Hala T, Bolognese M et al(DESCARTES Investigators) A 52-week
placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med. 2014;370(19):1809-19 https://www.ncbi.nlm.nih.gov/pubmed/24678979
10. Sabatine MS, Giugliano RP, Wiviott SD, et al (OSLER Investigators) Efficacy and safetyof evolocumab in reducing lipids and cardiovascular events. N Engl J Med.
2015;372(16):1500-9. https://www.ncbi.nlm.nih.gov/pubmed/25773607
11. Robinson JG, Farnier M, Krempf M et al (ODYSSEY LONG TERM Investigators) Efficacy
and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med.
2015;372(16):1489-99. https://www.ncbi.nlm.nih.gov/pubmed/25773378
12. Pfizer: Pfizer Discontinues Global Development of Bococizumab, Its Investigational PCSK9 Inhibitor
http://www.pfizer.com/news/press-release/press-release-detail/pfizer_discontinues_global_development_of_bococizumab_its_investigational_pcsk9_inhibitor
13. 日本神経学会、ギランバレー症候群、フィッシャー症候群診療ガイドライン 2013https://www.neurology-jp.org/guidelinem/gbs.html
14.家族性高コレステロール血症の方への対処について、薬のチェック TIP2016：16(6)：122-123.

New Productsp.10-11

参考文献
1. 薬のチェック TIP 編集部、GLP-1 作動剤（リラグルチドなど） 糖尿病患者の予後改善 の証拠なし、推奨しない．薬のチェック TIP 2016: 17(67):108-112.
http://www.npojip.org/chk_tip.html#No67
2.. 薬のチェック TIP 編集部、リラグルチドは心不全を悪化：LEADER 試験と逆の結果、薬のチェ
ック TIP、2016：16(68): 127-128
4

3.Editorial”糖尿病用薬剤の評価はなぜ“甘い”. 薬のチェック TIP、2016：16(67): 102
http://www.npojip.org/chk_tip/67-Editorial.pdf
4. MedCheckTIP editorial team. GLP-1 agonists No evidence of improving prognosis. MedCheckTIP inEnglish. 2016: 2(3): 36-42.
http://www.npojip.org/english/MedCheck/Med%20Check-TIP%2006-12-12.pdf
5. Marso SP et al Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016;
375(4):311-22. http://www.ncbi.nlm.nih.gov/pubmed/27295427
6. Margulies KB, et al , Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart
Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. JAMA. 2016 Aug 2;316(5):500-8.
http://www.ncbi.nlm.nih.gov/pubmed/27483064
7. 薬のチェック TIP 編集部、エンパグリフロジンも遮蔽不全の影響大、薬のチェック TIP、2016：
16(68): 142-143
8. Zinman B et al (EMPA-REG OUTCOME Investigators）Empagliflozin, Cardiovascular Outcomes,and Mortality in Type 2 Diabetes. N Engl J Med. 2015 Nov 26;373(22):2117-28
https://www.ncbi.nlm.nih.gov/pubmed/26378978
9. Ferdinand KC et al, Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: apre-specified meta-analysis of prospectively adjudicated cardiovascular events. Cardiovasc Diabetol.
2016;15:38 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4765050/
10. トルリシティ（デュラグルチド）審査報告書
11. 糖尿病と癌に関する委員会 糖尿病と癌に関する委員会報告, 糖尿病 56:374-390, 2013
12. トルリシティ（デュラグルチド）申請資料概要
13. Hori M, Matsuda T, Shibata A, Katanoda K, Sobue T, Nishimoto H, et al. Cancer incidence andincidence rates in Japan in 2009: a study of 32 population-based cancer registries for the Monitoring ofCancer Incidence in Japan (MCIJ) project. Japanese journal of clinical oncology. 2015;45(9):884-91.
http://ganjoho.jp/reg_stat/statistics/dl/index.html
14.Ferdinand KC et al, Effects of the once-weekly glucagon-like peptide-1 receptor agonist dulaglutide onambulatory blood pressure and heart rate in patients with type 2 diabetes mellitus. Hypertension.
2014;64(4):731-7.
15. Pyke C, et al., GLP-1 receptor localization in monkey and human tissue: novel distribution
revealed with extensively validated monoclonal antibody. Endocrinology, 2014; 155(4):1280-90 https://www.ncbi.nlm.nih.gov/pubmed/24467746
16.Kim M, et al., Nat Med, 2013; 19(5): 567-75. GLP-1 receptor activation and Epac2 link atrial natriuretic
peptide secretion to control of blood pressure.
https://www.ncbi.nlm.nih.gov/pubmed/23542788
17. Brunton LB et al. Goodman & Gilman’s The Pharmacological Basis of Therapeutics 12th ed
McGraw-Hill, 2011

5か月連続で最もよく読まれた論文
Free http://bmjopen.bmj.com/content/6/6/e010401.full.pdf+html
5

「コレステロール低下剤試験：相次いで中止」の参考文献
1) Eli Lilly and Company: Lilly To Discontinue Development Of Evacetrapib For High-Risk
Atherosclerotic Cardiovascular Disease
http://lilly.mediaroom.com/index.php?s=9042&item=137476
2. https://en.wikipedia.org/wiki/Torcetrapib
3. Schwartz GG et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome
N Engl J Med. 2012:;367(22):2089-99 https://www.ncbi.nlm.nih.gov/pubmed/23126252
4. https://en.wikipedia.org/wiki/Evacetrapib
5. Pfizer: Pfizer Discontinues Global Development of Bococizumab, Its Investigational PCSK9 Inhibitor
http://www.pfizer.com/news/press-release/press-release-detail/pfizer_discontinues_global_development_of_bococizumab_its_investigational_pcsk9_inhibitor

連載：医薬品安全性（危険性）情報

あれこれp12

日本の国立医薬品食品衛生研究所が発行している「医薬品安全性情報（海外規制機関）」から薬剤の害反応を紹介し、本誌編集委員がコメントする。
FDA：C型肝炎用剤:B型肝炎ウイルス再活性化を警告
NZ MEDSAFE：大豆ベースの医薬品添加物－落花生アレルギー患者にも問題か？
英MHRA：抗がん剤トラメチニブ:消化管穿孔と大腸炎のリスク

参考文献
1) Goodman LS & Gilman A edd, The Pharmacological Basis of Therapeutics 5th ed
Mcmillan, 1975
2) Meyler L and Herxheimer A ed Side Effects of Drugs. Vol 7 . Excerpta Medica 1972
3)長谷川剛、内藤真、NSAIDs が原因と考えられた下部消化管穿孔の 2 例、日本リンパ網内系会
誌、2009：49:132.
64)Kvasnovsky CL, Papagrigoriadis S, Bjarnason I. Increased diverticular complications with
nonsteriodal anti-inflammatory drugs and other medications: a systematic review andmeta-analysis. Colorectal Dis. 2014;16(6):O189-96
https://www.ncbi.nlm.nih.gov/pubmed/24320820
5) Gravante G, Yahia S. Medical influences, surgical outcomes: role of common medications
on the risk of perforation from untreated diverticular disease. World J Gastroenterol.
2013:19(36):5947-52. https://www.ncbi.nlm.nih.gov/pubmed/24106394
6) Thiéfin G, Beaugerie L. Toxic effects of nonsteroidal antiinflammatory drugs on the small bowel, colon,and rectum. Joint Bone Spine. 2005;72(4):286-94. https://www.ncbi.nlm.nih.gov/pubmed/16038840
7) 浜六郎、消化性潰瘍，消化管潰瘍を生じる薬剤、TIP 1997: 12(8/9):82-84.
8) Corder A. Steroids, non-steroidal anti-inflammatory drugs, and serious septic complicationsof diverticular disease. Br Med J 1987; 295: 1238.
https://www.ncbi.nlm.nih.gov/pubmed/3120962
9) Wilson RG, Smith AN, Macintyre IM. Complications of diverticular disease andnon-steroidal anti-inflammatory drugs: a prospective study. Br J Surg 1990; 77: 1103-4.
https://www.ncbi.nlm.nih.gov/pubmed/2121310
10) de Boer SY, Stolk MF et al. Non-steroidal ant-inflammatory drugs and inflammation ofthe colon. Ned Tijdschr Geneeskd 1989; 133: 883-6.
https://www.ncbi.nlm.nih.gov/pubmed/2725748
11) Goh H, Bourne R. Non-steroidal anti-inflammatory drugs and perforated diverticulardisease: a case-control study. Ann R Coll Surg Engl 2002; 84: 93-6.
https://www.ncbi.nlm.nih.gov/pubmed/11995772
12) Morris CR, Harvey IM, Stebbings WS et al. Anti-inflammatory rugs, analgesics and therisk of perforated colonic diverticular disease. Br J Surg 2003; 90: 1267-72.
https://www.ncbi.nlm.nih.gov/pubmed/14515298
13) Mpofu S, Mpofu CM, Hutchinson D et al. Steroids, non-steroidal anti-inflammatory drugs,and sigmoid diverticular abscess perforation in rheumatic conditions. Ann Rheum Dis
2004; 63: 588-90. https://www.ncbi.nlm.nih.gov/pubmed/15082493
14) Piekarek K, Israelsson LA. Perforated colonic diverticular disease: the importance ofNSAIDs, opioids, corticosteroids, and calcium channel blockers. Int J Colorectal Dis 2008;
23: 1193-7. https://www.ncbi.nlm.nih.gov/pubmed/18679693
15) Humes DJ, Fleming KM, Spiller RC et al. Concurrent drug use and the risk of perforated
colonic diverticular disease: a population-based case-control study. Gut 2011; 60: 219-24.
https://www.ncbi.nlm.nih.gov/pubmed/20940283
16)古賀秀樹、松本主之、飯田三雄、小腸の非ステロイド性抗炎症剤起因性潰瘍― 疫学・診断・治療―、日本消化器内視鏡学会雑誌 2008：50(2)：189-198.
17)浜六郎、宵越しの傷は持つな、虚血と離脱性炎症（WIR)、薬のチェックは命のチェック、2014：14 (56): 21-37.
18)市村宗ら、切除不能進行・再発胃癌の化学療法中に発症した消化管出血・血栓塞栓症・消化管穿孔症例の後方視的研究、癌と化学療法 2010: 37(11): 2131-6.
19) Sarela AI，Miner TJ，Karpeh MS，et al：Clinical outcomes with laparoscopic stage Ml，unresected gastric adenocarcinoma．Ann Surg. 2006: 243(2): 189-95
https://www.ncbi.nlm.nih.gov/pubmed/16432351
20) Shah MA，llson D，Kelsen DP，et al：Thromboembolic events in gastric cancer： highincidence in patients receiving irinotecan and bevacizumab based therapy ． Clin Oncol
2005:23(11): 2574-6．https://www.ncbi.nlm.nih.gov/pubmed/15795413
21) Shah MA, Ramanathan RK, Ilson DH et al Multicenter phase II study of irinotecan,
cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal
junction adenocarcinoma. J Clin Oncol. 2006;24(33): 5201-6
http://ascopubs.org/doi/pdf/10.1200/JCO.2006.08.0887
7参考文献と図書
1) 皮膚科学第7版、上野賢一著
2) 薬のチェックは命のチェック 31号(2008)、32号(2008)、37号(2010)
3) 患者に学んだ成人型アトピー治療、佐藤健二、つげ書房新社、2014
4) アトピッ子の素肌をつくる、隅田さちえ、子どもの未来社、2015
5) アトピー性皮膚炎患者1000人の証言、安藤直子、子どもの未来社、2008
6) 皮膚科診療カラーアトラス体系(1)、鈴木啓之他、KODANSHA、2008
7) Takahashi-Ando N, Jones MA, Fujisawa S, Hama R Patient-reported outcomes after discontinuation oflong-term topical corticosteroid treatment for atopic dermatitis: a targeted cross-sectional survey. Drug
Healthc Patient Saf. 2015 Apr 7;7:57-62.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4396455/pdf/dhps-7-057.pdf

p20-21

8

P22-24

P24
編集後記

9